普纳替尼联合化疗及移植治疗成人费城染色体阳性急性淋巴细胞白血病
PONALFIL试验将普纳替尼(30 mg/d)与标准化疗联合用于18至60岁新诊断费城染色体阳性急性淋巴细胞白血病患者,随后行异基因造血干细胞移植,移植后仅预防性使用普纳替尼。30例患者全部获血液学缓解,26例接受移植,3年无事件生存率和总生存率分别为70%和96%。倾向性评分比较显示PONALFIL较ALLPh08(伊马替尼)方案总生存显著改善(3年总生存率96% vs 53%,P=0.002)。
要点
- 普纳替尼30 mg/d联合标准化疗后行异基因造血干细胞移植,30例患者全部获血液学缓解。
- 26例接受移植者中20例达完全分子学缓解、6例达主要分子学缓解,移植后仅1例死于移植物抗宿主病。
- 3年无事件生存率70%(95%CI 51-89),3年总生存率96%(95%CI 89-100)。
核心结论
- 普纳替尼联合化疗后行异基因造血干细胞移植耐受良好,在新诊断费城染色体阳性急性淋巴细胞白血病成人中无事件生存率令人鼓舞。
- 跨试验比较提示普纳替尼方案较伊马替尼方案总生存改善(clinicaltrials.gov标识号NCT02776605)。
研究设计与样本
- PONALFIL试验将普纳替尼(30 mg/d)与标准诱导和巩固化疗联合,随后行异基因造血干细胞移植,用于18至60岁新诊断费城染色体阳性急性淋巴细胞白血病患者。
- 普纳替尼仅在异基因造血干细胞移植后预防性给予。
- 主要终点为移植前血液学和分子学缓解及无事件生存(包括分子学复发作为事件)。
- 30例患者入组,中位年龄49岁(范围19-59岁)。
主要发现
- 全部30例患者显示血液学缓解,26例接受异基因造血干细胞移植(20例完全分子学缓解,6例主要分子学缓解)。
- 仅1例患者死亡(死于移植物抗宿主病),5例患者在移植后出现分子学复发。
- 26例移植患者中18例在移植后未接受酪氨酸激酶抑制剂。
- 29例患者存活(中位随访2.1年,范围0.2-4.0年),3年无事件生存率和总生存率分别为70%(95%CI 51-89)和96%(95%CI 89-100)。
- 倾向性评分比较PONALFIL与ALLPh08(伊马替尼)试验显示PONALFIL组总生存显著改善(3年总生存率96% vs 53%,P=0.002)。
关键数值与推荐
- PONALFIL试验中普纳替尼剂量为30 mg/d,仅在异基因造血干细胞移植后预防性给予。
- 3年无事件生存率70%(95%CI 51-89),3年总生存率96%(95%CI 89-100)。
- PONALFIL组3年总生存率96% vs ALLPh08组53%(P=0.002)。
- 3至4级不良事件发生率:血液学42%、感染17%、肝脏22%。
临床怎么用
- 作者结论认为普纳替尼联合化疗后行异基因造血干细胞移植在新诊断费城染色体阳性急性淋巴细胞白血病成人中耐受良好且无事件生存率令人鼓舞。
- 作者指出跨试验比较提示普纳替尼方案较伊马替尼方案总生存改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Promising results have been shown with the combination of ponatinib and chemotherapy in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The PONALFIL (Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia) trial combined ponatinib (30 mg/d) with standard induction and consolidation chemotherapy followed by allogeneic hematopoietic stem cell transplant (alloHSCT) in newly diagnosed Ph+ ALL patients aged 18 to 60 years. Ponatinib was only given pre-emptively after alloHSCT. Primary end points were hematologic and molecular response before alloHSCT and event-free survival (EFS), including molecular relapse as event. Thirty patients (median age, 49 years; range, 19-59 years) entered the trial. All exhibited hematologic response, and alloHSCT was performed in 26 patients (20 in complete molecular response and 6 in major molecular response). Only 1 patient died (of graft-versus-host disease), and 5 patients exhibited molecular relapse after alloHSCT. No tyrosine kinase inhibitor was given after HSCT in 18 of 26 patients. Twenty-nine patients are alive (median follow-up, 2.1 years; range, 0.2-4.0 years), with 3-year EFS and overall survival (OS) of 70% (95% confidence interval, 51-89) and 96% (95% confidence interval, 89-100), respectively. Comparison of the PONALFIL and the ALLPh08 (Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph [BCR-ABL] Positive; same schedule, using imatinib as the tyrosine kinase inhibitor) trials by propensity score showed significant improvement in OS for patients in PONALFIL (3-year OS, 96% vs 53%; P = .002). The most frequent grade 3 to 4 adverse events were hematologic (42%), infectious (17%), and hepatic (22%), with only one vascular occlusive event. The combination of chemotherapy with ponatinib followed by alloHSCT is well tolerated, with encouraging EFS in adults with newly diagnosed Ph+ ALL. Cross-trial comparison suggests improvement vs imatinib (clinicaltrials.gov identifier #NCT02776605).
引用
- Ribera JM, García-Calduch O, Ribera J, et al. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Adv. 2022. PMID: 35675590. doi:10.1182/bloodadvances.2022007764
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。